FDA Advisory Panel Backs Approval of Pfizer, Affymax Drugs

Washington Drug Letter
A A
An FDA advisory committee unanimously backed Pfizer’s kidney cancer drug Inlyta as a second-line treatment for patients with advanced renal cell carcinoma (RCC).

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00